The role of drug-eluting stents for the treatment of coronary chronic total occlusions

Expert Review of Cardiovascular Therapy

Volumn 11, Issue 10, 2013, Pages 1349-1358

  Brilakis, Emmanouil S ^a   Kotsia, Anna ^a   Luna, Michael ^a   Garcia, Santiago ^b,c   Abdullah, Shuaib M ^a   Banerjee, Subhash ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b Minneapolis VA Healthcare System   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Chronic total occlusion; Drug eluting stents; Percutaneous coronary intervention

Indexed keywords

EVEROLIMUS; RAPAMYCIN; UMIROLIMUS; ZOTAROLIMUS;

BARE METAL STENT; BIOCOMPATIBILITY; DRUG ELUTING STENT; HEART INFARCTION; IN-STENT RESTENOSIS; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; REVIEW;

ABSORBABLE IMPLANTS; CORONARY RESTENOSIS; CORONARY STENOSIS; DRUG-ELUTING STENTS; HUMANS; PERCUTANEOUS CORONARY INTERVENTION; PROSTHESIS DESIGN; STENTS;

EID: 84886614339     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.2013.838142     Document Type: Review

References (63)

1. Garcia S, Abdullah S, Banerjee S, Brilakis ES. Chronic total occlusions: Patient selection and overview of advanced techniques. Curr. Cardiol. Rep. 15, 334 (2013).
2. Joyal D, Afilalo J, Rinfret S. Effectiveness of recanalization of chronic total occlusions: A systematic review and meta-Analysis. Am. Heart. J. 160, 179-187 (2010).
3. Khan MF, Wendel CS, Thai HM, Movahed MR. Effects of percutaneous revascularization of chronic total occlusions on clinical outcomes: A meta-Analysis comparing successful versus failed percutaneous intervention for chronic total occlusion. Catheter. Cardiovasc. Interv. 82, 95-107 (2013).
4. Muramatsu T, Hiranom K, Tsukahara R et al. Long-Term outcome of percutaneous transluminal coronary intervention for chronic total occlusion in the BMS era in Japan. Cardiovasc. Interv. Ther. 25, 78-84 (2010).
5. Werner GS, Surber R, Kuethe F et al. Collaterals and the recovery of left ventricular function after recanalization of a chronic total coronary occlusion. Am. Heart J. 149, 129-137 (2005).
6. Nombela-Franco L, Mitroi CD, Fernandez-Lozano I et al. Ventricular arrhythmias among implantable cardioverter-defibrillator recipients for primary prevention: Impact of chronic total coronary occlusion (VACTO Primary Study). Circ. Arrhythm. Electrophysiol. 5, 147-154 (2012).
7. Claessen BE, Dangas GD, Weisz G et al. Prognostic impact of a chronic total occlusion in a non-infarct-related artery in patients with ST-segment elevation myocardial infarction: 3-year results from the HORIZONS-AMI trial. Eur. Heart J. 33, 768-775 (2012).
8. Agostoni P, Valgimigli M, Biondi-Zoccai GG et al. Clinical effectiveness of bare-metal stenting compared with balloon angioplasty in total coronary occlusions: Insights from a systematic overview of randomized trials in light of the drug-eluting stent era. Am. Heart J. 151, 682-689 (2006).
9. Buller CE, Dzavik V, Carere RG et al. Primary stenting versus balloon angioplasty in occluded coronary arteries: The Total Occlusion Study of Canada (TOSCA). Circulation 100, 236-242 (1999).
10. Saeed B, Kandzari DE, Agostoni P et al. Use of drug-eluting stents for chronic total occlusions: A systematic review and meta-Analysis. Catheter. Cardiovasc. Interv. 77, 315-332 (2011).
11. Werner GS, Gitt AK, Zeymer U et al. Chronic total coronary occlusions in patients with stable angina pectoris: Impact on therapy and outcome in present day clinical practice. Clin. Res. Cardiol. 98, 435-441 (2009).
12. Claessen BE, van der Schaaf RJ, Verouden NJ et al. Evaluation of the effect of a concurrent chronic total occlusion on long-Term mortality and left ventricular function in patients after primary percutaneous coronary intervention. JACC Cardiovasc. Interv. 2, 1128-1134 (2009).
13. Tarantini G, Facchin M, Capodanno D et al. Paclitaxel versus sirolimus eluting stents in diabetic patients: Does stent type and/or stent diameter matter?: Long-Term clinical outcome of 2,429-patient multicenter registry. Catheter. Cardiovasc. Interv. 81, 80-89 (2013).
14. Buja P, Facchin M, Musumeci G et al. Paclitaxel- and sirolimus-eluting stents in older patients with diabetes mellitus: Results of a real-life multicenter registry. Catheter. Cardiovasc. Interv. 81, 1117-1124 (2013).
15. Brilakis ES, Saeed B, Banerjee S. Drug-eluting stents in saphenous vein graft interventions: A systematic review. EuroIntervention 5, 722-730 (2010).
16. Genereux P, Palmerini T, Caixeta A et al. Quantification and impact of untreated coronary artery disease after percutaneous coronary intervention: The residual SYNTAX (Synergy Between PCI with Taxus and Cardiac Surgery) score. J. Am. Coll. Cardiol. 59, 2165-2174 (2012).
17. Garcia S, Sandoval Y, Roukoz H et al. Outcomes after complete versus incomplete revascularization of patients with multivessel coronary artery disease: A meta-Analysis of 89,883 patients enrolled in randomized clinical trials and observational studies. J. Am. Coll. Cardiol. doi:10.1016/j. jacc.2013.05.033 (2013) (Epub ahead of print).
18. Colmenarez HJ, Escaned J, Fernandez C et al. Efficacy and safety of drug-eluting stents in chronic total coronary occlusion recanalization: A systematic review and meta-Analysis. J. Am. Coll. Cardiol. 55, 1854-1866 (2010).
19. Niccoli G, Leo A, Giubilato S et al. A meta-Analysis of first-generation drugeluting vs bare-metal stents for coronary chronic total occlusion: Effect of length of follow-up on clinical outcome. Int. J. Cardiol. 150, 351-354. (2011)
20. Ma J, Yang W, Singh M, Peng T, Fang N, Wei M. Meta-Analysis of long-Term outcomes of drug-eluting stent implantations for chronic total coronary occlusions. Heart Lung 40, e32-40 (2011).
21. Huang PH, Yeung M, Lasala JM et al. Two-year clinical outcomes with paclitaxel-eluting coronary stents in patients with chronic total occlusions: Analysis from the TAXUS ARRIVE program. J. Interv. Cardiol. 24, 232-240 (2011).
22. Kato M, Kimura T, Morimoto T et al. Comparison of five-year outcome of sirolimus-eluting stent implantation for chronic total occlusions versus for non-chronic total occlusion (from the j-Cypher registry). Am. J. Cardiol. 110, 1282-1289 (2012).
23. Mehran R, Claessen BE, Godino C et al. Long-Term outcome of percutaneous coronary intervention for chronic total occlusions. JACC Cardiovasc. Interv. 4, 952-961 (2011).
24. De Felice F, Fiorilli R, Parma A et al. Five-year outcomes in patients with chronic total coronary occlusion treated with drug-eluting vs bare-metal stents: A case-control study. Can. J. Cardiol. 29 (8), 945-950 (2012).
25. Kandzari DE, Rao SV, Moses JW et al. Clinical and angiographic outcomes with sirolimus-eluting stents in total coronary occlusions: The ACROSS/TOSCA-4 (Approaches to Chronic Occlusions With Sirolimus-Eluting S tents/Total Occlusion Study of Coronary Arteries-4) trial. JACC Cardiovasc. Interv. 2, 97-106 (2009).
26. Galassi AR, Tomasello SD, Costanzo L, Campisano MB, Barrano G, Tamburino C. Long-Term clinical and angiographic results of Sirolimus-Eluting stent in Complex coronary chronic Total Occlusion Revascularization: The SECTOR registry. J. Interv. Cardiol. 24, 426-436 (2011).
27. Patel MR, Marso SP, Dai D et al. Comparative effectiveness of drug-eluting versus bare-metal stents in elderly patients undergoing revascularization of chronic total coronary occlusions: Results from the National Cardiovascular Data Registry, 2005-2008. JACC Cardiovasc. Interv. 5, 1054-1061 (2012).
28. Kelbaek H, Helqvist S, Thuesen L et al. Sirolimus versus bare metal stent implantation in patients with total coronary occlusions: Subgroup analysis of the Stenting Coronary Arteries in Non-Stress/Benestent Disease (SCANDSTENT) trial. Am. Heart J. 152, 882-886 (2006).
29. Kelbaek H, Klovgaard L, Helqvist S et al. Long-Term outcome in patients treated with sirolimus-eluting stents in complex coronary artery lesions: 3-year results of the SCANDSTENT (Stenting Coronary Arteries in Non-Stress/Benestent Disease) trial. J. Am. Coll. Cardiol. 51, 2011-2016 (2008).
30. Suttorp MJ, Laarman GJ, Rahel BM et al. Primary stenting of totally occluded native coronary arteries II (PRISON II): A randomized comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions. Circulation 114, 921-928 (2006).
31. Van den Branden BJ, Rahel BM, Laarman GJ et al. Five-year clinical outcome after primary stenting of totally occluded native coronary arteries: A randomised comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions (PRISON II study). EuroIntervention 7, 1189-1196 (2012).
32. Rubartelli P, Petronio AS, Guiducci V et al. Comparison of sirolimus-eluting and bare metal stent for treatment of patients with total coronary occlusions: Results of the GISSOC II-GISE multicentre randomized trial. Eur. Heart J. 31, 2014-2020 (2010).
33. Reifart N, Hauptmann KE, Rabe A, Enayat D, Giokoglu K. Short and long term comparison (24 months) of an alternative sirolimus-coated stent with bioabsorbable polymer and a bare metal stent of similar design in chronic coronary occlusions: The CORACTO trial. EuroIntervention 6, 356-360 (2010).
34. Palmerini T, Biondi-Zoccai G, Della Riva D et al. Stent thrombosis with drug-eluting and bare-metal stents: Evidence from a comprehensive network meta-Analysis. Lancet 379, 1393-1402 (2012).
35. Stefanini GG, Holmes DR Jr. Drug-eluting coronary-Artery stents. N. Engl. J. Med. 368, 254-265 (2013).
36. Valenti R, Vergara R, Migliorini A et al. Predictors of reocclusion after successful drug-eluting stent-supported percutaneous coronary intervention of chronic total occlusion. J. Am. Coll. Cardiol. 61, 545-550 (2013).
37. Wohrle J, Rottbauer W, Imhof A. Everolimus-eluting stents for treatment of chronic total coronary occlusions. Clin. Res. Cardiol. 101, 23-28 (2012).
38. Valenti R, Vergara R, Migliorini A et al. Comparison of everolimus-eluting stent with paclitaxel-eluting stent in long chronic total occlusions. Am. J. Cardiol. 107, 1768-1771 (2011).
39. Almalla M, Hennings V, Marx N, Hoffmann R. Long-Term clinical and angiographic outcome after treatment of chronic total occlusion with everolimus or sirolimus eluting stents. Int. J. Cardiol. 157, 451-452 (2012).
40. Moreno R, Garcia E, Teles R et al. Randomized comparison of sirolimus-eluting and everolimus-eluting coronary stents in the treatment of total coronary occlusions: Results from the chronic coronary occlusion treated by everolimus-eluting stent randomized trial. Circ. Cardiovasc. Interv. 6, 21-28 (2013).
41. Park HJ, Kim HY, Lee JM et al. Randomized comparison of the efficacy and safety of zotarolimus-eluting stents vs. sirolimus-eluting stents for percutaneous coronary intervention in chronic total occlusion-CAtholic Total Occlusion Study (CATOS) trial. Circ. J. 76, 868-875 (2012).
42. Suttorp MJ, Laarman GJ. A randomized comparison of sirolimus-eluting stent implantation with zotarolimus-eluting stent implantation for the treatment of total coronary occlusions: Rationale and design of the PRImary Stenting of Occluded Native coronary arteries III (PRISON III) study. Am. Heart J. 154, 432-435 (2007).
43. Wohrle J, Werner GS. Paclitaxel-coated balloon with bare-metal stenting in patients with chronic total occlusions in native coronary arteries. Catheter. Cardiovasc. Interv. 81, 793-799 (2013).
44. Garcia S, Brilakis ES. Optimal stenting strategy for coronary chronic total occlusion interventions: What is next? Catheter. Cardiovasc. Interv. 81, 800-801 (2013).
45. Michael TT, Papayannis AC, Banerjee S, Brilakis ES. Subintimal dissection/reentry strategies in coronary chronic total occlusion interventions. Circ. Cardiovasc. Interv. 5, 729-738 (2012).
46. Colombo A, Mikhail GW, Michev I et al. Treating chronic total occlusions using subintimal tracking and reentry: The STAR technique. Catheter. Cardiovasc. Interv. 64, 407-411, discussion 12 (2005).
47. Godino C, Latib A, Economou FI et al. Coronary chronic total occlusions: Mid-Term comparison of clinical outcome following the use of the guided-STAR technique and conventional anterograde approaches. Catheter. Cardiovasc. Interv. 79, 20-27 (2012).
48. Brilakis ES, Grantham JA, Rinfret S et al. A percutaneous treatment algorithm for crossing coronary chronic total occlusions. JACC Cardiovasc. Interv. 5, 367-379 (2012).
49. Galassi AR, Tomasello SD, Costanzo L et al. Mini-STAR as bail-out strategy for percutaneous coronary intervention of chronic total occlusion. Catheter. Cardiovasc. Interv. 79, 30-40 (2012).
50. Lombardi WL. Retrograde PCI: What will they think of next? J. Invasive Cardiol. 21, 543 (2009).
51. Brilakis ES, Grantham JA, Thompson CA et al. The retrograde approach to coronary artery chronic total occlusions: A practical approach. Catheter. Cardiovasc. Interv. 79, 3-19 (2012).
52. Karmpaliotis D, Michael TT, Brilakis ES et al. Retrograde coronary chronic total occlusion revascularizationprocedural and in-hospital outcomes from a multicenter registry in the United States. JACC Cardiovasc. Interv. 5, 1273-1279 (2012).
53. Whitlow PL, Burke MN, Lombardi WL et al. Use of a novel crossing and re-entry system in coronary chronic total occlusions that have failed standard crossing techniques: Results of the FAST-CTOs (Facilitated Antegrade Steering Technique in Chronic Total Occlusions) trial. JACC Cardiovasc. Interv. 5, 393-401 (2012).
54. Lee NH, Seo HS, Choi JH, Suh J, Cho YH. Recanalization strategy of retrograde angioplasty in patients with coronary chronic total occlusion -Analysis of 24 cases, focusing on technical aspects and complications. Int. J. Cardiol. 144, 219-229 (2010).
55. Mogabgab O, Patel VG, Michael TT et al. Long-Term outcomes with use of the Bridgepoint Medical System for the recanalization of coronary chronic total occlusions. J. Invasive Cardiol. (2013) (In Press).
56. Park JJ, Chae IH, Cho YS et al. The recanalization of chronic total occlusion leads to lumen area increase in distal reference segments in selected patients: An intravascular ultrasound study. JACC Cardiovasc. Interv. 5, 827-836 (2012).
57. Galassi AR, Tomasello SD, Crea F et al. Transient impairment of vasomotion function after successful chronic total occlusion recanalization. J. Am. Coll. Cardiol. 59, 711-718 (2012).
58. Lee SP, Shin DH, Park KW et al. Angiographic patterns of restenosis after percutaneous intervention of chronic total occlusive lesions with drug-eluting stents. Int. J. Cardiol. 156, 180-185 (2012).
59. Liu W, Wagatsuma K, Nii H, Toda M, Amano H, Uchida Y. Impact of diabetes on long term follow-up of elderly patients with chronic total occlusion post percutaneous coronary intervention. J. geriatr. Cardiol. 10, 16-20 (2013).
60. Al-Lamee R, Ielasi A, Latib A et al. Clinical and angiographic outcomes after percutaneous recanalization of chronic total saphenous vein graft occlusion using modern techniques. Am. J. Cardiol. 106, 1721-1727 (2010).
61. Levine GN, Bates ER, Blankenship JC et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines and the Society for Cardiovascular Angiography and Interventions. J. Am. Coll. Cardiol. 58, e44-122 (2011).
62. Brilakis ES, Banerjee S. Advances in the treatment of coronary artery aneurysms. Catheter. Cardiovasc. Interv. 77, 1042-1044 (2011).
63. Teeuwen K, Adriaenssens T, Van den Branden BJ et al. A randomized multicenter comparison of hybrid sirolimus-eluting stents with bioresorbable polymer versus everolimus-eluting stents with durable polymer in total coronary occlusion: Rationale and design of the Primary Stenting of Occluded Native Coronary Arteries IV study. Trials 13, 240 (2012).